In short
Clinical trials are investigating Ibrutinib in many blood cancers and related conditions. These studies look at how well it works, how safe it is, and which treatment combinations or schedules may help different patient groups, including newly diagnosed, relapsed, and pediatric patients.
Key points
- Ibrutinib is being studied in many clinical trials for blood cancers and related conditions, especially CLL, SLL, mantle cell lymphoma, Waldenström’s macroglobulinemia, follicular lymphoma, and marginal zone lymphoma. The trial phases range from early safety studies to large Phase 3 and Phase 4 comparisons. Some studies test Ibrutinib alone, while others test it with drugs such as venetoclax, rituximab, obinutuzumab, or chemotherapy. Several trials focus on newly diagnosed patients, while others include relapsed or refractory disease. Key outcomes include progression-free survival, overall response rate, complete response, failure-free survival, MRD, and safety. A few studies also look at long-term access to treatment and pediatric use.
Clinical trials overview
The trial data show that Ibrutinib is being studied in many interventional trials, which means patients receive a planned treatment and the results are measured. The studies include Phase 1, Phase 2, Phase 3, Phase 3b, and Phase 4 trials, so the research covers early safety work and later comparison studies. Several trials are authorised, some are completed, and one listed study was withdrawn.
Many studies compare Ibrutinib with other active treatments, while others test it as part of a combination or as long-term follow-up after earlier treatment. The main goal across the trials is to learn how well treatment works and how safe it is in different patient groups.
Blood cancers studied in Ibrutinib trials
Most trials focus on chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Some of the largest studies compare Ibrutinib-based treatment with other first-line options in previously untreated CLL or CLL/SLL.
Other trials study Ibrutinib in mantle cell lymphoma (MCL), including untreated, relapsed/refractory, and older patient groups. There are also studies in Waldenström’s macroglobulinemia, follicular lymphoma, marginal zone lymphoma, and diffuse large B-cell lymphoma.
Some trials go beyond cancer and study Ibrutinib in chronic graft-versus-host disease (cGVHD), which is a condition that can happen after a transplant when the donor’s cells attack the patient’s body. One trial also studies Ibrutinib for autoimmune hemolytic anemia in people with CLL/SLL or CLL-like monoclonal B-cell lymphocytosis.
Treatment combinations and study designs
Some studies test Ibrutinib alone, while others combine it with drugs such as venetoclax, rituximab, or obinutuzumab.
In the CLL17 study, the trial compares continuous Ibrutinib alone with fixed-duration venetoclax plus obinutuzumab and fixed-duration venetoclax plus Ibrutinib. In the TAILOR study, researchers are testing tailored Ibrutinib treatment regimens and comparing them with historical controls, which means older trial results used as a comparison group.
In mantle cell lymphoma, some trials compare Ibrutinib plus rituximab with chemotherapy-based treatment, while others test Ibrutinib with venetoclax and rituximab. Another Phase 4 study in older patients compares rituximab/Ibrutinib with rituximab/chemotherapy.
A few studies use Ibrutinib in more complex treatment plans, such as CAR-T-cell trials or basket studies, where one study includes several related patient groups or diseases.
Main endpoints measured in the trials
The most common endpoint is progression-free survival (PFS), which measures how long patients live without the disease getting worse.
Many studies also measure overall response rate (ORR), which is the share of patients whose disease shrinks or disappears by the study rules. Some trials look at complete response (CR), very good partial response (VGPR), or complete remission, which means the disease is not found or is much smaller after treatment.
Several trials use minimal residual disease (MRD) as an endpoint. MRD means a very small amount of disease that can remain after treatment and needs very sensitive tests to detect it.
Safety is also important, especially in early-phase studies. These trials measure dose-limiting toxicities, adverse events, laboratory changes, vital signs, and ECG changes, which are checks on heart rhythm and electrical activity.
Who can participate
Eligibility depends on the trial and the disease stage. Some studies include previously untreated patients, meaning they have not had treatment for that disease before.
Other studies include relapsed or refractory patients, meaning the disease returned after treatment or did not respond well to earlier therapy. Some studies also ask for patients with specific risk features, such as high-risk markers, TP53 changes, or a certain International Prognostic Index score.
One study includes physically fit patients with creatinine clearance of at least 30 ml/min, which is a measure of kidney function. Another trial focuses on pediatric patients, including children from age 1 to under 22 years with cGVHD.
Special patient groups
Some trials focus on patients with special disease features, such as TP53 aberrations, which means changes in a gene linked with treatment resistance and disease behavior. One study follows the size of TP53-mutated subclones over time, which helps researchers see how the cancer cell population changes during treatment.
Other studies focus on people who are not in complete remission or who still have detectable MRD after treatment. In the NEXT STEP trial, Ibrutinib and obinutuzumab are being used to try to convert these patients to MRD-negative complete remission.
There are also studies in older patients with untreated mantle cell lymphoma, where the goal is to see whether rituximab/Ibrutinib performs better than rituximab/chemotherapy. This shows that the research includes both newly diagnosed and more vulnerable patient groups.
Long-term access and extension studies
Some trials are not designed to start a new treatment strategy but to give continued access to Ibrutinib for patients who were already benefiting from it. These extension studies also collect long-term safety and efficacy data, which means they track how well treatment keeps working and what side effects or other problems appear over time.
One long-term protocol includes many disease groups, such as follicular lymphoma, CLL, Waldenström macroglobulinemia, multiple myeloma, marginal zone lymphoma, diffuse large B-cell lymphoma, urothelial carcinoma, breast cancer, acute myeloid leukemia, graft-versus-host disease, and mantle cell lymphoma. This shows that Ibrutinib is being followed in a broad range of ongoing study settings, not only in one disease.
References in this article are based on the trial records listed below.